Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

• Status: Completed
• Trial end date: 2007-01-01

Summary

The objectives of this study are to evaluate the safety and efficacy of 3 dose groups (27, 36 and 45 mg/m2) of Combretastatin A-4 Phosphate for the treatment of subfoveal choroidal neovascularization in subjects with pathologic myopia.

• Phase: Phase 2

Details

• Lead Sponsor: Mateon Therapeutics
• Treatments: Combretastatin; Fosbretabulin